2024
International Prognostic Score for Nodular Lymphocyte–Predominant Hodgkin Lymphoma
Binkley M, Flerlage J, Savage K, Akhtar S, Steiner R, Zhang X, Dickinson M, Prica A, Major A, Hendrickson P, Hopkins D, Ng A, Casulo C, Baron J, Roberts K, Al Kendi J, Balogh A, Ricardi U, Torka P, Specht L, De Silva R, Pickard K, Blazin L, Henry M, Smith C, Halperin D, Brady J, Brennan B, Senchenko M, Reeves M, Hoppe B, Terezakis S, Talaulikar D, Picardi M, Kirova Y, Fergusson P, Hawkes E, Lee D, Doo N, Barraclough A, Cheah C, Ku M, Hamad N, Mutsando H, Gilbertson M, Marconi T, Viiala N, Maurer M, Eichenauer D, Hoppe R, Borchmann P, Fuchs M, Hartmann S, Eich H, Lo A, Skinnider B, Rauf M, Maghfoor I, Pinnix C, Milgrom S, Vega F, Alomari M, Collins G, Advani R, Metzger M, Wirth A, Tsang R, Smith S, Kelsey C, McKay P, Koenig J, Constine L, Sakthivel K, Plastaras J, Gao S, Al Rahbi N, Levis M, Sridhar A, Shah N, Osborne W, Chang I, Miall F, Mikhaeel G, Penn A, Volchkov E, Della Pepa R, Northend M, Opat S, Salvaris R, Tedjaseputra A, Palese M, Shankar A, Natkunam Y, Kelly K. International Prognostic Score for Nodular Lymphocyte–Predominant Hodgkin Lymphoma. Journal Of Clinical Oncology 2024, 42: 2271-2280. PMID: 38531001, DOI: 10.1200/jco.23.01655.Peer-Reviewed Original ResearchNodular lymphocyte-predominant Hodgkin lymphomaProgression-free survivalLymphocyte-predominant Hodgkin lymphomaInternational Prognostic ScoreImmunoarchitectural patternsOverall survivalHodgkin lymphomaPrognostic scoreSplenic involvementAssociated with worse progression-free survivalAssociated with progression-free survivalDe-escalation of therapyMedian follow-upAge of patientsProspective clinical trialHigh-risk patientsStage III-IVClinical risk factorsRisk of transformationStage I to IIB symptomsAdult patientsIII-IVActive surveillanceRare cancers
2023
Radiotherapy Utilization and Outcomes on a Contemporary Trial for Pediatric High-Risk Hodgkin Lymphoma Study
Hoppe B, Castellino S, Pei Q, Charpentier A, Keller F, Vega R, Roberts K, Parikh R, Punnett A, Parsons S, McCarten K, Flampouri S, Kessel S, Wu Y, Cho S, Kelly K, Hodgson D. Radiotherapy Utilization and Outcomes on a Contemporary Trial for Pediatric High-Risk Hodgkin Lymphoma Study. International Journal Of Radiation Oncology • Biology • Physics 2023, 117: s62-s63. DOI: 10.1016/j.ijrobp.2023.06.362.Peer-Reviewed Original ResearchProgression-free survivalBrentuximab vedotinABVE-PCIrradiated patientsMediastinal adenopathyRadiotherapy utilizationContemporary trialsRT modalityOpen-label phase 3 studyExcellent progression-free survivalUse of PTProgression-free survival ratesProton therapyHodgkin's lymphoma studyUtilization of RTSevere acute toxicityPhase 3 studyPediatric Hodgkin lymphomaSimilar acute toxicityAcute toxicityMATERIAL/METHODSDifferent RT modalitiesEligible patientsMedian followPediatric patients
2020
Stage I-II nodular lymphocyte-predominant Hodgkin lymphoma: a multi-institutional study of adult patients by ILROG
Binkley M, Rauf M, Milgrom S, Pinnix C, Tsang R, Dickinson M, Ng A, Roberts K, Gao S, Balogh A, Ricardi U, Levis M, Casulo C, Stolten M, Specht L, Plastaras J, Wright C, Kelsey C, Brady J, Mikhaeel N, Hoppe B, Terezakis S, Picardi M, Della Pepa R, Kirova Y, Akhtar S, Maghfoor I, Koenig J, Jackson C, Song E, Sehgal S, Advani R, Natkunam Y, Constine L, Eich H, Wirth A, Hoppe R. Stage I-II nodular lymphocyte-predominant Hodgkin lymphoma: a multi-institutional study of adult patients by ILROG. Blood 2020, 135: 2365-2374. PMID: 32211877, DOI: 10.1182/blood.2019003877.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedCombined Modality TherapyFemaleFollow-Up StudiesHodgkin DiseaseHumansKaplan-Meier EstimateLymphoma, Large B-Cell, DiffuseMaleMiddle AgedNeoplasm StagingNeoplasms, Radiation-InducedNeoplasms, Second PrimaryPositron Emission Tomography Computed TomographyProgression-Free SurvivalProportional Hazards ModelsRecurrenceRetrospective StudiesSalvage TherapySurvival AnalysisTreatment OutcomeYoung AdultConceptsNodular lymphocyte-predominant Hodgkin lymphomaProgression-free survivalOverall survivalImmunoarchitectural patternsAssociated with worse progression-free survivalFive-year PFSLymphocyte-predominant Hodgkin lymphomaProgression-free survival ratesStudy of adult patientsSingle-agent rituximabLarge-cell transformationStage I diseaseMedian follow-upMulticenter retrospective studyMulti-institutional studyHodgkin lymphomaI diseaseRT cohortHistological variantsMedian agePrimary managementRetrospective studyRituximabAdult patientsRadiotherapy